A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects

Inclusion Criteria: 1. Male or female subjects, 18-75 years of age at the time of signing informed consent; 2. At screening visit, BMI ≥ 28 kg/m2 or ≥ 24 kg/m2 with at least one weight-related comorbidity; 3. Diet and exercise control for at least 3 months before screening visit, and the weight change does not exceed 5% within the last 3 months; 4. Able and willing to provide a written informed consent. Exclusion Criteria: 1. Presence of clinically significant lab or ECG results that may affect the evaluation of the efficacy or safety of the study drug at screening visit; 2. Uncontrollable severe hypertension; 3. PHQ-9 score ≥ 15; 4. Medical history or illness that affects body weight; 5. History of diabetes; 6. Acute or chronic hepatitis; 7. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to screening; 8. Any organ-system malignancies developed within 5 years; 9. Acute infection, acute trauma, or medium to large surgery within 30 days prior to screening; 10. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness, mentally incapacitated or speech-impaired; 11. Use of any medication or treatment that may have caused significant weight change within 90 days; 12. History of bariatric surgery; 13. Known or suspected hypersensitivity to trial product(s) or related products; 14. History of alcohol and/or substance abuse or drug abuse; 15. History of blood donation or blood loss in the 3 months before screening, or blood transfusion in the 2 months before screening; 16. Surgery is planned during the trial; 17. The investigators determined that other conditions were inappropriate for participation in this clinical trial.